Distinguished in Heart Failure

Hans Eiskjaer

Palle Juul Jensens Boulevard 99, 
Aarhus N, DK 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Heart Failure
Palle Juul Jensens Boulevard 99, 
Aarhus N, DK 
OverviewLocationsClinical Research

Overview

Hans Eiskjaer practices in Aarhus N, Denmark. Mr. Eiskjaer is rated as a Distinguished expert by MediFind in the treatment of Heart Failure. His top areas of expertise are Heart Failure, Cardiac Arrest, Cardiogenic Shock, Heart Transplant, and Lung Transplant.

His clinical research consists of co-authoring 158 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 52 articles in the study of Heart Failure.

Gender
Male

Locations

Palle Juul Jensens Boulevard 99, Aarhus N, 8200, Denmark
Other Locations
Palle Juul Jensens Boulevard 82, Aarhus N, 8200, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

DAPARHT: DAPAgliflozin for Renal Protection in Heart Transplant Recipients
DAPARHT: DAPAgliflozin for Renal Protection in Heart Transplant Recipients
Enrollment Status: Recruiting
Publish Date: October 03, 2024
Intervention Type: Drug
Study Phase: Phase 3
Effects of Advanced Mechanical Circulatory Support in Patients With ST Segment Elevation Myocardial Infarction Complicated by Cardiogenic Shock. The Danish Cardiogenic Shock Trial
Effects of Advanced Mechanical Circulatory Support in Patients With ST Segment Elevation Myocardial Infarction Complicated by Cardiogenic Shock. The Danish Cardiogenic Shock Trial
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Device
Study Phase: Not Applicable
5, 6 or 7 Year Follow-up Control After the SCHEDULE Study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE)
5, 6 or 7 Year Follow-up Control After the SCHEDULE Study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE)
Enrollment Status: Completed
Publish Date: October 03, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 2 Less Clinical Trial

158 Total Publications

Long-Term Outcomes of the DanGer Shock Trial.
Long-Term Outcomes of the DanGer Shock Trial.
Journal: The New England journal of medicine
Published: September 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Eiskjaer's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 13 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile